Cytoreductive Nephrectomy May Improve Survival in ICI-Treated mRCC
In the era of immune checkpoint inhibitors, cytoreductive nephrectomy retains an important role in mRCC in carefully selected patients, according to investigators.
Diagnosis & Disease Information
Younger Black Men Have Worst Survival in the mRCC Population
Possible reasons for the survival disparity include differences in obesity and smoking incidence among Black men younger than 50 years.
PD-L1 Expression May Help Predict BCG Response in High-Grade NMIBC
Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators.
Cytokines Linked With Survival Outcomes in Nivolumab-Treated mRCC
Validation of the cytokine markers within the entire NIVOREN study is ongoing.
Bladder Cancer Drug Shows Antitumor Activity in Cisplatin-Ineligible Patients
Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.
Early Salvage Radiation After RP Improves Outcomes in Relapsed Prostate Cancer
Early-salvage radiation therapy was associated with reduced risks for biochemical recurrence and metastasis, compared with expectant management.
Sarcopenia Ups Risk for Major mRCC Surgery Complications
Screening for sarcopenia may assist in identifying patients at high risk for increased perioperative morbidity, according to investigators.
Durable Responses to COVID-19 Vaccines Seen in Cancer Patients on Immunotherapy
Patients receiving immunotherapy had a more durable immune response to vaccination, compared with patients receiving chemotherapy or targeted therapy.
No Benefit With Adjuvant Mitotane in Low/Intermediate-Risk Adrenocortical Carcinoma
Adjuvant mitotane does not improve outcomes in patients with adrenocortical carcinoma at low or intermediate risk of relapse after surgery.
Molecular Features of Primary and Metastatic Sites Differ in Renal Cell Carcinoma
New findings could inform personalized therapeutic strategies for patients with renal cell carcinoma, according to investigators.
- Loading...
Loading...
Next post in ASCO GU 2022
Loading... 
Loading...